Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Sachpekidis, Christos [VerfasserIn]   i
 Larribere, Lionel [VerfasserIn]   i
 Hassel, Jessica C. [VerfasserIn]   i
 Dimitrakopoulou-Strauss, Antonia [VerfasserIn]   i
Titel:Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?
Verf.angabe:Christos Sachpekidis, Lionel Larribère, Annette Kopp-Schneider, Jessica C. Hassel, Antonia Dimitrakopoulou-Strauss
E-Jahr:2019
Jahr:26 November 2018
Umfang:7 S.
Fussnoten:Im Titel ist "18" in 18F-FDG PET/CT hochgestellt ; Gesehen am 10.05.2019
Titel Quelle:Enthalten in: Cancer immunology immunotherapy
Ort Quelle:Berlin : Springer, 1976
Jahr Quelle:2019
Band/Heft Quelle:68(2019), 2, Seite 297-303
ISSN Quelle:1432-0851
Abstract:BackgroundAn association between immune-related adverse events (irAEs) caused by immunotherapeutic agents and the clinical benefit of immunotherapy has been suggested. We retrospectively evaluated by means of 18F-FDG PET/CT lymphoid tissue changes in the mediastinal/hilar lymph nodes and the spleen in response to ipilimumab administration in metastatic melanoma.MethodsA total of 41 patients with unresectable metastatic melanoma underwent 18F-FDG PET/CT before the start of ipilimumab (baseline PET/CT), after two cycles (interim PET/CT) and at the end of treatment (late PET/CT). Data analysis was focused on the mediastinal/hilar lymph nodes and the spleen. The patients’ best clinical response (BCR) was used as reference.ResultsAccording to the BCR reference, 31 patients showed disease control (DC) and 10 patients showed progressive disease (PD). Mediastinal/hilar lymph node evaluation revealed that in total 4 patients in the interim or late PET/CT (10%) demonstrated a ‘sarcoid-like lymphadenopathy’ as response to treatment (LN-positive). All LN-positive patients responded to ipilimumab with DC. On the other hand, no significant differences between the DC and PD groups regarding both semi-quantitative and quantitative 18F-FDG PET spleen-related parameters at baseline and as response to treatment were detected.ConclusionBased on our findings, 10% patients in the interim or late PET/CT showed ‘sarcoid-like lymphadenopathy’ as response to treatment. All these patients showed disease control, implying a relation between the appearance of sarcoid-like lymphadenopathy and the clinical benefit of anti-CTLA-4 therapy. On the other hand, quantitative 18F-FDG PET analysis of the spleen showed a poor performance in predicting clinical benefit to ipilimumab.
DOI:doi:10.1007/s00262-018-2279-9
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1007/s00262-018-2279-9
 DOI: https://doi.org/10.1007/s00262-018-2279-9
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:‘Sarcoid-like lymphadenopathy’
 18F-FDG PET/CT
 Ipilimumab
 Metastatic melanoma
 Spleen glucose metabolism
K10plus-PPN:1665161752
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68388688   QR-Code
zum Seitenanfang